Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Product-news symbols : Pfe save search
European Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal Disease
Published: 2024-03-13 (Crawled : 11:00) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: 1.0%
H: 1.41%
C: -0.25%
disease pneumococcal children
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
elrexfio
European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata
Published: 2023-09-19 (Crawled : 09:00) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: -0.27%
H: 1.37%
C: 1.31%
ViiV Healthcare initiates rolling submission of new drug application with US FDA for long-acting cabotegravir for prevention of HIV
Published: 2021-05-04 (Crawled : 13:00) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: 0.43%
H: 0.43%
C: -0.13%
GSK | $39.44 -0.4% 560K
|
Health Technology
|
| O: -0.19%
H: 0.29%
C: -0.27%
new drug fda drug hiv submission application
Pfizer Acquires Amplyx Pharmaceuticals
Published: 2021-04-28 (Crawled : 12:00) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: 0.23%
H: 1.04%
C: 0.7%
Astellas Receives Positive CHMP Opinion for XTANDI™ (enzalutamide) for Patients with Metastatic Hormone-Sensitive Prostate Cancer
Published: 2021-03-26 (Crawled : 13:15) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: 0.03%
H: 1.71%
C: 1.6%
prostate cancer positive cancer hormone chmp
EMA Accepts Marketing Application for Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency
Published: 2021-02-26 (Crawled : 14:00) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: 0.06%
H: 0.18%
C: -1.03%
OPK | $1.245 -0.4% 1.4M
|
Health Technology
|
| O: 4.82%
H: 0.58%
C: -2.87%
growth hormone growth hormone ema application
Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ® (tofacitinib) in Subjects with Rheumatoid Arthritis (RA)
Published: 2021-01-27 (Crawled : 14:00) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: -0.86%
H: 0.14%
C: -2.03%
results rheumatoid arthritis
Pfizer and BioNTech Receive CHMP Positive Opinion for their COVID-19 Vaccine
Published: 2020-12-21 (Crawled : 15:00) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: -1.06%
H: 0.32%
C: 0.27%
BNTX | $86.085 -0.37% 160K
|
Health Technology
|
| O: 3.14%
H: 0.43%
C: -0.98%
covid vaccine positive chmp covid-19
BAVENCIO® (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Published: 2020-12-11 (Crawled : 15:00) - biospace.com/
PFE A | $25.325 -0.37% 15M
|
Health Technology
|
| O: 0.58%
H: 0.24%
C: -2.03%
positive treatment chmp urothelial carcinoma
Gainers vs Losers
| 80% | 20% |
Top 10 Gainers
AGBA | $0.7995 99.88% 73M
|
Finance
BPTH | $6.21 91.67% 58M
|
Health Technology
INVO | $1.36 78.95% 3.6M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Your saved searches
Save your searches and get alerts when important news are released.